Oncology NEWS International Vol 23 No 5

Earlier Unrelated BMT Is Effective in CML Subgroup

February 01, 1996

SEATTLE--Early donor matching and transplant appear to be particularly important in improving survival rates in chronic myeloid leukemia (CML) patients receiving unrelated donor marrow, John A. Hansen, MD, said at the plenary session of the American Society of Hematology annual meeting. In fact, he said, in selected patients, survival rates approach those of patients receiving marrow from HLA-identical siblings.

Taxol/Cisplatin Extends Survival in Advanced Ovarian Ca

February 01, 1996

PHILADELPHIA--Women with advanced ovarian cancer had 50% longer survival when they received a first-line regimen combining paclitaxel (Taxol) and cisplatin (Platinol), says William P. McGuire, MD, and his colleagues in the Gynecology Oncology Group (GOG).

Prostate Cancer Patients Face a Host of Psychosocial Issues

February 01, 1996

PALM SPRINGS, Calif--Early diagnosis of prostate cancer can be a mixed blessing, bringing with it not only the chance of cure but also the psychological distress of choosing between watchful waiting and treatment, and if treatment is chosen, which treatment, Andrew Roth, MD, said at the Academy of Psychosomatic Medicine meeting.

NSABP to Study Docetaxel in Operable Breast Cancer

February 01, 1996

COLLEGEVILLE, Penn--Rhône-Poulenc Rorer Inc. and the National Surgical Adjuvant Breast and Bowel Project (NSABP) have announced the initiation of a new clinical trial (B-27) utilizing docetaxel (Taxotere) in women with operable breast cancer.

Panel Recommends Approval of Talc for Malignant Pleural Effusions

February 01, 1996

BETHESDA, Md--The Oncologic Drugs Advisory Committee (ODAC) has recommended that Sclerosol (sterile aerosol talc) be approved for use in relieving fluid around the lungs (malignant pleural effusion) of patients with cancer. The sponsor for Sclerosol, Bryan Corporation (Woburn, Mass), presented nine controlled trials (six articles and three abstracts), with an average of 12 patients each, in support of the talc.

ODAC Recommends Approval of Verluma for Staging of SCLC

February 01, 1996

BETHESDA, Md--The Oncologic Drugs Advisory Committee (ODAC), in a vote of 9 to 4, recommended that Verluma imaging be approved for the initial staging of patients with biopsy-confirmed small-cell lung cancer (SCLC). Verluma is a murine monoclonal antibody (MoAb) Fab fragment, targeted to the NR-LU-10 antigen and linked to technetium-99m.

Minorities Lack Internet Access to Cancer Research Data

February 01, 1996

BETHESDA, Md--Cable television, not computers, may be the best way to reach the poor with information about cancer research, Harold P. Freeman, MD, said at a meeting of the National Cancer Advisory Board (NCAB) that focused on issues of minority recruitment into clinical trials.

Fludarabine Produces CRs as First-Line CLL Therapy

February 01, 1996

SEATTLE--Fludarabine (Fludara) has demonstrated impressive results in previously untreated patients with active chronic lymphocytic leukemia (CLL) when compared with chlorambucil (Leukeran), Kanti Rai, MD, said at the American Society of Hematology (ASH) annual meeting.

M.D. Anderson's C. Stratton Hill Receives Award From American Cancer Society

February 01, 1996

CHICAGO--The American Cancer Society has presented its Humanitarian Award to C. Stratton Hill, Jr., MD, of the University of Texas M.D. Anderson Cancer Center. The award is given for dedication to thea improvement of cancer control and genuine accomplishment in human welfare.

Managed Care: The View From Salick Managed Care

February 01, 1996

In the past few years, this country has seen a major change in the financing of health care. According to a recent survey by Foster Higgins, an international employee-benefits consulting agency, at the end of 1994, 63% of all privately insured Americans were enrolled in a managed care plan.

Selling 'High Risk' Part of an Oncology Practice Can Increase Financial Stability

February 01, 1996

MARINA DEL REY, Calif--Comparing the technical services portion of an oncology practice to a car that has been driven 25,000 miles, Dean H. Gesme, Jr., MD, managing partner of Iowa Cancer Care, P.L.C., said that he and his partners decided to spin off that part of their Cedar Rapids practice while it still had a high market value.

High-Dose RAIT May Improve Prognosis in Relapsed NHL Patients

February 01, 1996

NEW YORK--Attaching iodine-131 to the anti-CD20(B1) antibody (radioimmunotherapy or RAIT) may provide durable remissions in relapsed non-Hodgkin's lymphomas (NHL), Oliver Press, MD, PhD, said at a symposium sponsored by the New York City-based Cancer Research Institute.

Photofrin Available for Esophageal Palliation

February 01, 1996

WASHINGTON--The FDA has approved QLT PhotoTherapeutics' light-activated drug Photofrin (porfimer sodium) for the palliative treatment of esophageal constriction in patients with advanced esophageal cancer.

Cytogenetic Studies Continue to Yield Important Ca Research Data

February 01, 1996

SEATTLE--With advanced molecular genetic techniques now available to researchers for the identification and study of genes involved in cancer, the question arises: Is the study of chromosomal translocations, additions, and deletions still a worthwhile pursuit?

Expert Panel Dispels Misinformation About Tamoxifen

February 01, 1996

An expert panel of seven cancer researchers and a patient advocate came together at the San Antonio Breast Cancer Symposium for a roundtable discussion on tamoxifen (Nolvadex), sponsored by PRR, Inc., publisher of Oncology News International and the journal ONCOLOGY.

Zoladex 3-Month Depot Implant Is Approved

February 01, 1996

WILMINGTON, Del--Zeneca Pharmaceuticals has received clearance from the FDA to market a new formulation of Zoladex (goserelin acetate implant) for the palliative treatment of advanced prostate cancer.

Sphincter-Preserving Surgery Plus Preop RT Effective in Distal Segment Rectal Ca

February 01, 1996

MIAMI BEACH--Sphincter-preserving surgical techniques can be safely and effectively combined with high-dose preoperative radiation for tumors in the most distal segments of the rectum, Mohammed Mohiuddin, MD, said at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting.

Angiogenesis Precedes Breast Cancer Development, Van Nuys Study Shows

February 01, 1996

SAN ANTONIO--Mammographic signs of angiogenesis and neovascularity may identify a developing breast cancer years before the lesion becomes visible, Parvis Gamagami, MD, said at the San Antonio Breast Cancer symposium.

Which Non-Hodgkin's Lymphoma Patients Benefit From ABMT?

February 01, 1996

I would like to take issue with Dr. Bruce Cheson's response to a reader's question on the role of high-dose chemotherapy/autologous bone marrow transplantation (ABMT) in patients with non-Hodgkin's lymphoma (Oncology News International, December, 1995, page 25).

Golde Named Physician-in Chief at Memorial Hospital

February 01, 1996

NEW YORK--Dr. David W. Golde has been appointed Physician-in-Chief of Memorial Hospital, Dr. Paul Marks, president of Memorial Sloan-Kettering Cancer Center, announced. Dr. Golde succeeds Joseph V. Simone, MD, who is to become clinical director for the Huntsman Cancer Institute, Salt Lake City.

Women With HIV at Risk for Undermanagement of Depression

February 01, 1996

PALM SPRINGS, Calif--Women with HIV represent the fastest growing segment of the epidemic and are among the most vulnerable for the undermanage-ment of both pain and psychological distress, Robert Boland, MD, and Margaret McDonald, CSW, said at the Academy of Psychosomatic Medicine meeting.

Preop 5-FU May Avoid Mastectomy in High Risk Early Breast Ca

February 01, 1996

NEW YORK--Women facing mastectomy because of high-risk early breast cancer may benefit from a new strategy that reduces tumor size, allowing conservative surgery or eliminating the need for surgery, Ian E. Smith, MD, said at the symposium of the Chemotherapy Foundation.